Abstract
Controversies exist on the role of tyrosine in the pathogenesis of phenylketonuria (PKU) and, consequently, on the therapeutic role of tyrosine. This review examines data and theoretical considerations on the role of tyrosine in the pathogenesis and treatment of PKU. It is concluded that treatment with tyrosine alone to replace the phenylalanine-restricted diet cannot be justified. A treatment with large neutral amino acids (LNAA) including tyrosine to restore the balance in the transport of phenylalanine and other LNAA across the blood–brain barrier deserves further investigation. Such studies should prove the safety and the efficacy of such a treatment, finding the optimal dose of all LNAA, disclosing the correct age to start and the way to monitor treatment biochemically.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
REFERENCES
Batshaw ML,Valle D,Bessman SP (1981) Unsuccessful treatment of phenylketonuria with tyrosine. J Pediatr 99: 159–160.
Berry HK,Bo¡nger MK,Hunt MM,Philips PJ,Guilfoile MK (1982) Reduction of cerebrospinal £uid phenylalanine after oral administration of valine, isoleucine, and leucine. Pediatr Res 16: 751–755.
Berry HK,Brunner RL,Hunt MM, et al (1990) Valine, isoleucine and leucine. A new treat-ment for phenylketonuria. Am J Dis Child 144: 539–543.
Bessman SP (1972) Genetic failure of fetal amino acid 'justi¢cation': a common basis for many forms of metabolic, nutritional, and 'nonspeci¢c' mental retardation. J Pediatr 81: 834–842.
Bessman SP (1998) Historical perspective: tyrosine and maternal phenylketonuria, welcome news. Am J Clin Nutr 67: 357–358.
Diamond A (1996) Evidence for the importance of dopamine for prefrontal cortex functions early in life. Phil Trans R Soc Lond B 351: 1483–1494.
Koch R (1996) Tyrosine supplementation for phenylketonuria treatment. Am J Clin Nutr 64: 974–975.
Lenke RL,Levy HL (1980) Maternal phenylketonuria and hyperphenylalaninemia. An in-ternational survey of the outcome of untreated and treated pregnancies. N Engl JMed 303: 1202–1208.
Lenke RR,Koch R,Fishler K,Platt LD (1983) Tyrosine supplementation during pregnancy in a woman with classical phenylketonuria. A case report. J Reprod Med 28: 411–414.
Leuzzi V,Fois D,Carducci C,Antonozzi I,Trasimeni G (1997) Neuropsychological and neuroradiological (MRI) variations during phenylalanine load: protective e¡ect of valine, leucine and isoleucine supplementation. J Child Neurol 12: 338–340.
Lou HC (1985) Large doses of tryptophan and tyrosine as potential therapeutic alternative to dietary phenylalanine restriction in phenylketonuria. Lancet II: 150–151.
Lou HC,Güttler F,Lykkelund C,Bruhn P,Niederwieser A (1985) Decreased vigilance and neurotransmitter synthesis after discontinuation of dietary treatment for phenylketonuria in adolescents. Eur J Pediatr 144: 17–20.
Lou HC,Lykkelund C,Gerdes AM,Udesen H,Bruhn P (1987) Increased vigilance and dopamine synthesis by large doses of tyrosine or phenylalanine restriction in phenylketonuria. Acta Paediatr Scand 76: 560–565.
Mazzocco MM,Yannicelli S,Nord AM, et al (1992) Cognition and tyrosine supplementation among school-aged children with phenylketonuria. Am J Dis Child 146: 1261–1264.
McKean CM (1972) The effect of high phenylalanine concentrations on serotonin and catecholamine metabolism in the human brain. Brain Res 47: 469–476.
Paans AMJ,Pruim J, Smit GPA,Visser G,Willemsen ATM,Ullrich K (1996) Neurotrans-mitter positron emission tomographic studies in adults with phenylketonuria, a pilot study. Eur J Pediatr 155(supplement 1): S78–81.
Pennington BC,van Doorninck WJ,McCabe LL,McCabe ERB (1985) Neuropsychological de¢cits in early treated phenylketonuric children. Am J Ment De¢c 89: 467–474.
Pietz J,Landwehr R,Kutscha A,Schmidt H,de Sonneville L,Trefz FK (1995) Effect of high-dose tyrosine supplementation on brain function in adults with phenylketonuria. J Pediatr 127: 936–943.
Pietz J,Kreis R,Rupp A, et al (1999) Large neutral amino acids block phenylalanine transport into brain tissue in patients with phenylketonuria. J Clin Invest 103: 1169–1178.
Scriver CR,Kaufman S,Woo SLC (1995) The hyperphenylalaninemias. In Scriver CR,Beaudet AL,Sly WS,Valle D, eds. TheMetabolic andMolecular Bases of InheritedDisease, 7th edn. New York: McGraw-Hill, 1015–1075.
Smith ML,Hanley BW,Clarke JTR, et al (1998) Randomised controlled trial of tyrosine supplementation on neuropsychological performance in phenylketonuria. Arch Dis Child 78: 116–121.
Stemerdink BA (1996) Early and continuously treated phenylketonuria. An experimental neuropsychological approach. Thesis, University of Amsterdam.
Ullrich K,Weglage J,Oberwittler C, et al (1994) Effects of L-DOPA on pattern visual evoked potentials (P-100) and neuropsychological tests in untreated adult patients with phenylketonuria. J Inherit Metab Dis 17: 349–352.
van Spronsen, Paans AMJ,Willemsen ATM,Smit GPA (1999) PKU treatment beyond childhood. The use of positron emission tomography (PET) to design a well-balanced treatment. J Inherit Metab Dis 22(supplement 1): 1.
Welsh MC,Pennington BF,Ozonoff S,Rouse B,McCabe ERB (1990) Neuropsychology of early-treated phenylketonuria: specific executive function deficits. Child Dev 61: 1697–1713.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
van Spronsen, F.J., Smit, P.G.A. & Koch, R. Phenylketonuria: Tyrosine beyond the phenylalanine-restricted diet. J Inherit Metab Dis 24, 1–4 (2001). https://doi.org/10.1023/A:1005689232358
Issue Date:
DOI: https://doi.org/10.1023/A:1005689232358